>>> US Gapping up

Gapping up
Select Index ETFs showing strength:
  • QQQ +1.5%, IWM +1.4%, SPY +1.2%, DIA +0.9%
Other news:
  • AZEK +19.9% (AZEK and James Hardie (JHX) to merge creating a leading building products growth platform; both co's reaffirm guidance)
  • LAES +6% (Co and WeCanGroup Sign Strategic Agreement for SEALSQ to Acquire a 30% Stake in WeCanGroup)
  • QBTS +4.7% (files for 5,000,000 common stock offering by selling shareholder)
  • RIOT +4.2% (enters non-binding term sheet to acquire certain assets of Rhodium and settlement agreement)
  • VALN +4% (responds to French Government's request for vaccine supply of IXCHIQ against Chikungunya outbreak in La Réunion)
  • TSLA +3.6% (aims to halt driving assistance trial software in China before approval, according to Reuters)
  • LRMR +3.5% (Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results)
  • SVCO +3.1% (announces resignation of CFO Ryan Benton)
  • USGO +1.9% (applauds U.S. Presidential Executive Order Recognizing Copper & Gold as 'Critical Minerals' - Strong Economic and Policy Tailwinds will benefit Whistler Gold-Copper Project, Alaska)
  • LAZR +1.8% (entered into private exchange agreements with certain holders outstanding 1.25% Convertible Senior Notes due 2026 to exchange $18.2 million of Notes for newly issued shares of Class A common stock)
  • TRDA +1.7% (received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to initiate ELEVATE-45-201)
  • BA +1.5% (Bell Boeing Joint Program Office awarded a $590 mln U.S Navy contract modification)
  • FITB +1.2% (files mixed shelf securities offering)
  • TRGP +1.2% (files mixed shelf securities offering)
  • STLA +1.2% (reports sales in February)
  • CDXS +1.2% (reports first revenue-generating contract for ECO Synthesis Manufacturing Services)
  • BLK +1.1% (files mixed shelf securities offering)
  • VERV +1.1% (announces the clearance of its Investigational New Drug application by the FDA for VERVE-102)
  • X +1% (Highlights Proven Track Record and Commitment to Delivering Stockholder Value in Definitive Proxy Statement and Stockholder Letter)